Literature DB >> 23313142

Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma.

Feng Tian1, Dajiang Li, Jian Chen, Wei Liu, Lei Cai, Jianwei Li, Peng Jiang, Zipei Liu, Xin Zhao, Fei Guo, Xiaowu Li, Shuguang Wang.   

Abstract

AIM: GATA6, a zinc-finger transcription factor, functions as a tumour promoter or suppresser according to different tumour origins. We investigated the clinical significance of GATA6 and its role in invasion and metastasis in cholangiocarcinoma (CCA).
METHODS: Expression of GATA6 in 87 cancerous, 24 paracancerous, 32 lymph-node metastatic and 8 liver metastatic samples from 87 CCA patients undergoing surgical resection was detected by immunohistochemistry. Impact of GATA6 on invasion, metastasis and 67kDa laminin receptor expression (67LR) was evaluated in CCA cells by shRNA lentivirus or expressed-plasmid transfection.
RESULTS: Aberrant expression of GATA6 in CCAs was significantly associated with lymph-node metastasis. GATA6 expression was higher in lymph-node and liver metastatic tissues compared with primary cancerous tissues. Kaplan-Meier analysis showed GATA6 expression correlated with poor overall survival and early recurrence in CCAs. Cox analysis suggested GATA6 was an independent prognostic marker for overall survival and recurrence-free survival. CCA cell invasion and migration were decreased by GATA6 knockdown and enhanced by GATA6 overexpression in vitro. Knockdown of GATA6 reduced CCA cell metastasis by xenotransplantation into nude mice. 67LR, which is overexpressed in CCAs and promotes invasion and metastasis through several pathways, positively correlated with GATA6 expression in 87 CCAs. Both mRNA and protein levels of 67LR were regulated by GATA6 in CCA cells. Moreover, ChIP analysis showed GATA6 bound to 67LR gene promoter in CCA cells.
CONCLUSION: Aberrant expression of GATA6 correlates with poor prognosis and promotes invasion and metastasis in CCA.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23313142     DOI: 10.1016/j.ejca.2012.12.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  16 in total

1.  lncRNA SNHG16 Mediates Cell Proliferation and Apoptosis in Cholangiocarcinoma by Directly Targeting miR-146a-5p/GATA6 Axis.

Authors:  Tao Wu; Ming-Sheng Lei; Xu-Zhao Gao; Ting-Gang Xiong; Kang Yang; Qian Gong; Rui Tang; Yue-Peng Tian; Xiao-Hua Fu
Journal:  Biochem Genet       Date:  2021-04-02       Impact factor: 1.890

Review 2.  Molecular diagnosis of intrahepatic cholangiocarcinoma.

Authors:  Hiroaki Haga; Tushar Patel
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-09-29       Impact factor: 7.027

3.  A new clinically based staging system for perihilar cholangiocarcinoma.

Authors:  Roongruedee Chaiteerakij; William S Harmsen; Carlos Romero Marrero; Mohammed M Aboelsoud; Albert Ndzengue; Joseph Kaiya; Terry M Therneau; William Sanchez; Gregory J Gores; Lewis R Roberts
Journal:  Am J Gastroenterol       Date:  2014-11-11       Impact factor: 10.864

4.  The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling.

Authors:  Kumiko Umemoto; Hiroyuki Yamamoto; Ritsuko Oikawa; Hiroyuki Takeda; Ayako Doi; Yoshiki Horie; Hiroyuki Arai; Takashi Ogura; Takuro Mizukami; Naoki Izawa; Jay A Moore; Ethan S Sokol; Yu Sunakawa
Journal:  J Natl Cancer Inst       Date:  2022-09-09       Impact factor: 11.816

5.  EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma.

Authors:  Mariko Tanaka; Junji Shibahara; Shumpei Ishikawa; Tetsuo Ushiku; Teppei Morikawa; Aya Shinozaki-Ushiku; Akimasa Hayashi; Kento Misumi; Atsushi Tanaka; Hiroto Katoh; Kei Sakuma; Takashi Kokudo; Yoshinori Inagaki; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Masashi Fukayama
Journal:  Virchows Arch       Date:  2018-10-23       Impact factor: 4.064

6.  miR-124 targets GATA6 to suppress cholangiocarcinoma cell invasion and metastasis.

Authors:  Feng Tian; Jian Chen; Shuguo Zheng; Dajiang Li; Xin Zhao; Peng Jiang; Jianwei Li; Shuguang Wang
Journal:  BMC Cancer       Date:  2017-03-07       Impact factor: 4.430

7.  miR-196b promotes lung cancer cell migration and invasion through the targeting of GATA6.

Authors:  Hongli Li; Chao Feng; Songtao Shi
Journal:  Oncol Lett       Date:  2018-05-08       Impact factor: 2.967

8.  Comprehensive analysis of the GATA transcription factor gene family in breast carcinoma using gene microarrays, online databases and integrated bioinformatics.

Authors:  Shan Yu; Xuepeng Jiang; Juan Li; Chao Li; Mian Guo; Fei Ye; Maomao Zhang; Yufei Jiao; Baoliang Guo
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

9.  The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma.

Authors:  Tao Peng; Xiang Deng; Feng Tian; Zhonghu Li; Peng Jiang; Xin Zhao; Guangyu Chen; Yan Chen; Ping Zheng; Dajiang Li; Shuguang Wang
Journal:  Int J Oncol       Date:  2019-07-15       Impact factor: 5.650

10.  Prognostic significance of the combined expression of neutral endopeptidase and dipeptidyl peptidase IV in intrahepatic cholangiocarcinoma patients after surgery resection.

Authors:  Jianyong Zhu; Xiaodong Guo; Baoan Qiu; Zhiyan Li; Nianxin Xia; Yingxiang Yang; Peng Liu
Journal:  Onco Targets Ther       Date:  2014-02-17       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.